Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK reports pivotal Phase III results showing its investigational hepatitis B therapy bepirovirsen achieved markedly higher functional cure rates than current treatments. In pooled B‑Well 1 and 2 trials, 6‑month bepirovirsen plus standard of care produced a 19% functional cure in adults with baseline HBsAg ≤3000 IU/mL, versus 0% with standard care alone.
Among participants with baseline HBsAg ≤1000 IU/mL, who represent a large share of diagnosed cases, the functional cure rate reached 26% versus 0% on placebo. An exploratory analysis found 49% of bepirovirsen recipients had qHBsAg ≤100 IU/mL one year after treatment ended, a level associated with stronger immune control.
Bepirovirsen also delivered sustained HBV DNA suppression in 23% of all treated participants and 31% of those starting with HBsAg ≤1000 IU/mL, with safety generally characterized by injection‑site reactions and transient liver enzyme elevations. The drug is under priority review in the US and other major markets, with first regulatory decisions expected in Q3 2026.
GSK plc reported an insider transaction involving President Maya Martinez-Davis. She acquired notional American Depositary Shares (ADS) through her GSK Executive Supplemental Savings Plan account. The plan credited 9.293 ADS at a price of $51.3800 per ADS on May 22, 2026, with the transaction executed on the New York Stock Exchange.
GSK plc has admitted a further 45,273 ordinary shares of 31¼ pence each to trading on the London Stock Exchange Main Market. These shares were issued under existing block listing admissions for the “GlaxoSmithKline plc Share Save Plan 2022”. Following this admission, a total of 4,316,221,551 GSK ordinary shares are admitted to trading, and the new shares are fully fungible with existing ordinary shares.
GSK plc reports that, under its existing share buyback programme and a non-discretionary agreement with Citigroup Global Markets Limited, it repurchased ordinary shares on the London market between 18 and 22 May 2026.
On those dates, GSK bought between about 329,000 and 339,000 shares per day at volume‑weighted average prices ranging from 1,867.02 GBp to 1,918.46 GBp. Since 11 May 2026, the company has repurchased 3,342,149 ordinary shares, which are being held as treasury shares.
After these purchases, GSK holds 264,720,435 ordinary shares in treasury and has 4,051,501,116 ordinary shares in issue excluding treasury. The total number of voting rights is 4,051,501,116, and GSK states that treasury shares represent 6.53% of voting rights for regulatory disclosure calculations.
GSK plc outlines its financial reporting and dividend timetable for the remainder of 2026. The company plans to publish its Q2 2026 results on Tuesday 28 July 2026 via the London Stock Exchange and will also provide an update on portfolio growth opportunities at that time.
The schedule lists announcement, ex-dividend, record, dividend election and payment dates for Q2, Q3 and Q4 2026. For Q2 2026, the cash dividend is scheduled to be paid on Thursday 8 October 2026, for Q3 2026 on Thursday 7 January 2027, and for Q4 2026 on Thursday 8 April 2027. All dates are described as indicative and may be subject to change.
GSK plc reported a routine insider transaction by non-executive director Dr Hal Barron. On 2026-05-15, Dr Barron acquired 74 GSK American Depositary Shares at $49.6700 per ADS through dividend reinvestment in his GSK 401(k) plan account on the New York Stock Exchange.
GSK plc disclosed that Non-Executive Director Dr Hal Barron acquired 74 American Depositary Shares at $49.6700 each through dividend reinvestment in his GSK 401(k) plan. The transaction took place on May 15, 2026 on the New York Stock Exchange.
GSK plc reported automatic acquisitions of notional American Depositary Shares by three senior figures through its Executive Supplemental Savings Plan. Dr Hal Barron, a non-executive director, acquired 2,300.572 notional ADS at $49.6700 per ADS following dividend reinvestment. On the same terms and date, James Ford, SVP and Group General Counsel, acquired 54.387 notional ADS and Maya Martinez-Davis, President, acquired 82.387 notional ADS. All transactions took place on 2026-05-15 on the New York Stock Exchange.
GSK plc reports recent purchases of its own ordinary shares under its existing buyback programme, executed through Citigroup Global Markets Limited. Between 11 and 15 May 2026, the company repurchased daily amounts ranging from 323,368 to 342,412 shares at volume-weighted average prices around 1,855–1,882 GBp.
The purchased shares will be held as Treasury shares. Since 11 May 2026, GSK has bought a total of 1,671,851 ordinary shares. After these transactions, it holds 263,050,137 shares in treasury and has 4,053,167,539 ordinary shares in issue, which is also the total number of voting rights.
The company states that, in line with DTR 5.5.1R, 6.49% of voting rights are attributable to treasury shares. Shareholders can use the updated voting rights figure to assess whether they must notify their holdings under the UK Disclosure Guidance and Transparency Rules.
GSK plc reports that Japan's Ministry of Health, Labour and Welfare has expanded approval of its RSV vaccine Arexvy to include adults aged 18-49 years at increased risk for RSV disease. The vaccine was already approved for all adults 60 and older and adults 50-59 at increased risk, making this the first RSV vaccine in Japan covering all at-risk adults 18-59 plus all adults 60 and above.
The label in Japan now explicitly recognises immunocompromised patients as an increased-risk group, helping clinicians identify more people who may benefit. The decision is supported by Phase IIIb, Phase III and Phase IIb data showing non-inferior immune responses in younger at-risk adults and a safety profile consistent with earlier trials, with mostly mild to moderate, transient side effects such as injection site pain, myalgia, fatigue, arthralgia and headache.